Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Fell Today

By Joe Tenebruso – Updated Aug 17, 2020 at 6:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Intensifying competition could weigh on the biotech's growth.

What happened 

Shares of Sorrento Therapeutics (SRNE -6.51%) declined on Monday after a new competing saliva-based COVID-19 test received emergency use authorization from the Food and Drug Administration. By the close of trading, Sorrento's stock was down 3% after falling as much as 18% earlier in the day. 

So what 

Sorrento's stock price rose sharply in late July and early August after the biopharmaceutical company signed a licensing agreement with Columbia University for a saliva-based rapid diagnostic test that detects the novel coronavirus in as little as 30 minutes. Sorrento believed that, if approved by regulators, the test could be used in a wide variety of settings, such as airports and sporting events, as well as for at-home testing. 

A person wearing gloves is placing a swab in a laboratory test vial.

Sorrento Therapeutics' stock fell as a new competitor emerged in the coronavirus testing market. Image source: Getty Images.

But on Saturday, the Yale School of Public Health said the FDA had granted its saliva-based diagnostic test (which had been funded in part by the NBA and National Basketball Players Association) an emergency use authorization. Yale says the test, called SalivaDirect, is "highly sensitive" and produces results similar to nasal-swab-based tests. It's also inexpensive, with an expected cost of roughly $10 per sample. 

Now what 

The emergence of Yale's COVID-19 test could reduce the potential market opportunity for Sorrento's test. But it's important to note that Sorrento's procedure does not need to be completed in a laboratory, which could make it more attractive than Yale's method in certain settings. Perhaps that's why Sorrento's stock recovered most of its losses by the market close.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.58 (-6.51%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.